RxDoctor Payments Data

Ghazal Jameel

Nurse Practitioner · Tampa, FLNPI 1902237548

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $26,005 of the $41,367 with a category attached, or 62.9%. AVEO Pharmaceuticals, Inc. accounts for 61.8% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $27,843 and has fallen 95.3% since, to $1,309 in 2025. Among nurse practitioner clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$41,367in general payments, 2019–2025

Across 121 payments — averaging $341.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AVEO Pharmaceuticals, Inc.$26K
  • Sanofi$14K
  • Astellas Pharma Global Development$1K
  • Exelixis Inc.$465
  • Bayer$354
  • AstraZeneca$84
  • plus $90 from 4 others

What the payments were for

  • Consulting fees$4,39411%
  • Speaking & faculty fees$26,00563%
  • Travel & lodging$8,15420%
  • Food & beverage$2,4316%
  • Education$3841%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,367 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$62,744
Medicare patients
260
Services billed
850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide53$743,062
InlytaAxitinib30$589,091
NubeqaDarolutamide26$356,865
CabometyxCabozantinib S-Malate14$276,307
Everolimus13$116,159
Abiraterone Acetate49$112,377
OrgovyxRelugolix17$50,534
Nilutamide11$47,672
Bicalutamide95$3,292
Prednisone73$420
Ondansetron Hcl11$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerInlyta$31$589,09130 claims
BayerNubeqa$354$356,86526 claims
Exelixis Inc.Cabometyx$465$276,30714 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$23$112,37749 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →